NEUROMetrix
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NEUROMetrix - overview
Established
1996
Location
Waltham, MA, US
Primary Industry
Medical Devices & Equipment
About
NeuroMetrix focuses on developing advanced non-invasive medical devices that diagnose and treat pain and neurological disorders. Their flagship product is the FDA-authorized Quell® Fibromyalgia device, designed to alleviate chronic pain symptoms. Founded in 1996 in Waltham, US, NeuroMetrix specializes in non-invasive medical technology. The company has executed a total of 3 deals, with its most recent deal in July 2004 being a PIPE deal that raised USD 18.
70 mn. Shai Gozani serves as the CEO. NeuroMetrix, Inc. specializes in the development of non-invasive medical devices focused on the diagnosis and treatment of pain and neurological disorders.
Its flagship product, the Quell® Fibromyalgia device, is the first FDA-authorized medical device specifically designed to alleviate symptoms associated with fibromyalgia. The device modulates nerve activity through electrical stimulation, potentially reducing pain perception for conditions such as lower extremity and low back pain. NeuroMetrix markets its products to healthcare providers and patients suffering from chronic pain, aiming to reach over 5 million users globally. In the most recent year of 2024, NeuroMetrix reported a revenue of USD 3.
03 mn with an EBITDA of USD -8. 69 mn. The company utilizes a direct-to-consumer sales model, primarily selling its Quell device through online channels, while also potentially partnering with healthcare providers and retailers to enhance market accessibility. NeuroMetrix plans to leverage recent funding to support the development of new products and expand its market presence.
The company is targeting specific global markets for expansion and aims to introduce additional offerings that enhance pain management solutions. The most recent funding round in July 2004, which involved pricing its initial public offering, will help facilitate these growth initiatives.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
www.neurometrix.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
NEUROMetrix - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 10,396,775 | 7,575,289 | 5,278,806 | 5,512,764 | 7,299,830 | 12,027,528 | 17,092,336 | 16,090,138 | 9,272,522 | 7,377,975 | 8,253,493 | - | - | - |
| % Revenue Growth (YoY) | - | (27.1%) | (30.3%) | 4.4% | 32.4% | 64.8% | 42.1% | (5.9%) | (42.4%) | (20.4%) | 11.9% | - | - | - |
| EBITDA (USD) | (9,626,095) | (9,724,930) | (7,208,177) | (8,624,949) | (13,053,594) | (14,956,618) | (12,820,284) | (12,121,855) | (11,410,699) | (2,004,950) | (2,208,229) | - | - | - |
| Operating Income (USD) | (10,003,027) | (10,022,027) | (7,358,840) | (8,770,049) | (13,276,186) | (15,207,945) | (13,082,618) | (12,291,567) | (11,534,711) | (2,094,904) | (2,284,607) | - | - | - |
| Operating Margin | (96.2%) | (132.3%) | (139.4%) | (159.1%) | (181.9%) | (126.4%) | (76.5%) | (76.4%) | (124.4%) | (28.4%) | (27.7%) | - | - | - |
| % EBITDA Margin | (92.6%) | (128.4%) | (136.5%) | (156.5%) | (178.8%) | (124.4%) | (75.0%) | (75.3%) | (123.1%) | (27.2%) | (26.8%) | - | - | - |
| NET Income (USD) | (9,981,105) | (10,007,553) | (8,019,137) | (7,766,222) | (9,187,348) | (14,913,151) | (12,859,253) | 23,605 | (3,773,014) | (2,092,195) | (2,281,457) | - | - | - |
| % Net Margin | (96.0%) | (132.1%) | (151.9%) | (140.9%) | (125.9%) | (124.0%) | (75.2%) | 0.1% | (40.7%) | (28.4%) | (27.6%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.